NCT07031102 Methacholine Challenge Test in School Children With/Without Asthma RISKA
| NCT ID | NCT07031102 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Helsinki University Central Hospital |
| Condition | Asthma Bronchiale |
| Study Type | OBSERVATIONAL |
| Enrollment | 260 participants |
| Start Date | 2024-11-06 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 260 participants in total. It began in 2024-11-06 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study includes a pre-study telephone interview with healthy controls to assess their eligibility for participation. During the study visit, a background information form and an asthma questionnaire are completed. At the study visit, a methacholine challenge test measuring airway hyperresponsiveness and an exhaled nitric oxide measurement are performed. The effect of medication intensification in asthma patients is further assessed through a telephone interview 1-2 months after the medication adjustment.
Eligibility Criteria
Inclusion Criteria: Healthy Controls * • Aged 7-15 years, both sexes * No diagnosis of asthma in childhood * No inhaled asthma medication during the previous 2 years * No wheezing or shortness of breath during the previous 2 years * Written informed consent from the participant and guardian Inclusion Criteria: Children with Asthma * Aged 7-15 years, both sexes * Physician-diagnosed asthma (ICD-10 codes J45.0/J45.1/J45.9) * Inhaled corticosteroid treatment for at least 6 months * Either: * Well-controlled asthma (c-ACT/ACT score ≥20) and no clinical need to intensify medication, or * Poorly controlled asthma with physician-confirmed need for intensified asthma medication Exclusion Criteria: * • Premature birth before 32 gestational weeks * Other chronic cardiopulmonary or neurological conditions affecting airways (excluding asthma) * Severe underlying illness such as malignancy * Beta-blocker medication * Active immunological disease
Contact & Investigator
Mika Mäkelä, Professor, PhD, MD
STUDY CHAIR
HUS
Frequently Asked Questions
Who can join the NCT07031102 clinical trial?
This trial is open to participants of all sexes, aged 7 Years or older, up to 15 Years, studying Asthma Bronchiale. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07031102 currently recruiting?
Yes, NCT07031102 is actively recruiting participants. Contact the research team at janne.burman@hus.fi for enrollment information.
Where is the NCT07031102 trial being conducted?
This trial is being conducted at Helsinki, Finland.
Who is sponsoring the NCT07031102 clinical trial?
NCT07031102 is sponsored by Helsinki University Central Hospital. The principal investigator is Mika Mäkelä, Professor, PhD, MD at HUS. The trial plans to enroll 260 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.